Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the ...
EVANSTON, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced four upcoming poster …